Deucravacitinib improves PASI scores in patients with plaque psoriasis
Jeffrey M. Sobell, MD Credit: Tufts Medical Center Patients with moderate-to-severe plaque psoriasis receiving deucravacitinib showed improvements in efficacy, including Psoriasis Area and Severity Index (PASI) scores and static Physicians’ Global Assessment (sPGA) response rates, according to data presented at the Fall 2023 Clinical Dermatology Conference.1 These results, observed at week 16, continued to improve …